Market openNon-fractional
Silverback Therapeutics/SPRY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Silverback Therapeutics
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Ticker
SPRY
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
25
Website
ars-pharma.com
SPRY Metrics
BasicAdvanced
$881M
Market cap
-
P/E ratio
-$0.52
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$881M
Financial strength
Current ratio
60.899
Quick ratio
60.197
Total debt to equity
0.097
Management effectiveness
Return on assets (TTM)
-15.54%
Return on equity (TTM)
-20.49%
Valuation
Price to revenue (TTM)
87,403.846
Price to book
3.92
Price to tangible book (TTM)
3.92
Price to free cash flow (TTM)
-16.24
Growth
Revenue change (TTM)
-98.51%
Earnings per share change (TTM)
-31.56%
What the Analysts think about SPRY
Analyst Ratings
Majority rating from 3 analysts.
SPRY Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$10M
43.66%
Profit margin
0.00%
NaN%
SPRY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.18
-$0.16
-$0.07
-$0.11
-
Expected
-$0.17
-$0.18
-$0.14
-$0.11
-$0.13
Surprise
3.65%
-12.41%
-50.00%
0.00%
-
SPRY News
AllArticlesVideos
The Schall Law Firm Commences Inquiry Into Allegations Against ARS Pharmaceuticals Inc And Urges Affected Investors To Get Involved
Accesswire·2 days ago
Probe Into Claims Against ARS Pharmaceuticals Inc Initiated By The Schall Law Firm And Impacted Investors Are Encouraged To Participate
Accesswire·3 days ago
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Silverback Therapeutics stock?
Silverback Therapeutics (SPRY) has a market cap of $881M as of July 05, 2024.
What is the P/E ratio for Silverback Therapeutics stock?
The price to earnings (P/E) ratio for Silverback Therapeutics (SPRY) stock is 0 as of July 05, 2024.
Does Silverback Therapeutics stock pay dividends?
No, Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Silverback Therapeutics dividend payment date?
Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders.
What is the beta indicator for Silverback Therapeutics?
Silverback Therapeutics (SPRY) does not currently have a Beta indicator.
Buy or sell Silverback Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.